ONL Therapeutics Promotes New Lead Drug, Expands Clinical Program
Xconomy Detroit – 7/6/15
by Sarah Schmid
ONL Therapeutics, a University of Michigan spin-out working on sight-preserving therapies for retinal diseases, announced that it has changed course in its drug development program. The company has promoted a new lead drug candidate and has expanded its planned clinical studies to include both dry and wet forms of age-related macular degeneration (AMD).